Collection of Circulating Biomarkers in Pancreatic Cancer
NCT ID: NCT05743049
Last Updated: 2025-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30 participants
OBSERVATIONAL
2023-02-27
2028-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
NCT02471170
Project Survival-Prospective Biomarker Discovery
NCT02781012
Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants
NCT00898482
Studying Biomarkers in Patients With Pancreatic Cancer
NCT00900003
Pancreatic Cancer Biomarker Study
NCT04143152
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blood specimens
Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma.
Obtaining blood for analysis of various circulating biomarkers
4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Obtaining blood for analysis of various circulating biomarkers
4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject must be a patient of the University of Pennsylvania
* The subject must be able to provide informed consent
* The subject must be 18 years of age or older
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abramson Cancer Center at Penn Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark O'Hara, MD
Role: PRINCIPAL_INVESTIGATOR
Abramson Cancer Center, University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
852628
Identifier Type: OTHER
Identifier Source: secondary_id
UPCC 20222
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.